# EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer

> **NCT03494322** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University College, London** · enrollment: 130 (estimated)

## Conditions studied

- Head and Neck Cancer
- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT03494322
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-07-20
- **Primary completion:** 2021-09-15
- **Final completion:** 2024-10-31
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2024-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03494322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03494322, "EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03494322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*